Gujarat Kidney And Super Speciality Limited Announces 7th AGM on Sep 28, 2026
Gujarat Kidney And Super Speciality Limited will hold its 7th AGM on September 28, 2026. The agenda includes adopting FY26 financial statements, appointing directors, approving secretarial auditors, and revising remuneration for MD (₹18L to ₹36L) and Whole-time Director (₹18L to ₹24L). Members will also vote on borrowing powers up to ₹500 Cr.
The AGM agenda includes significant proposals such as director appointments, remuneration revisions, and substantial borrowing powers (up to ₹500 Crores), which can impact the company's future operations and financial structure. The approval of financial statements and auditor appointments are also key governance events.
The announcement is a routine corporate event (AGM notice) detailing various business proposals including financial statement adoption, director appointments, and remuneration adjustments. While these are important for governance, they do not inherently suggest a positive or negative outlook for the company's performance.
Gujarat Kidney And Super Speciality Limited has announced the upcoming 7th Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM is scheduled to be held on Monday, September 28, 2026, at 9:30 a.m. in physical mode at the Company's registered office in Vadodara.
The agenda for the AGM includes several key items. Ordinary Business will cover the adoption of the audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, along with the Directors' and Auditors' reports. Additionally, a Director retiring by rotation will be considered for re-appointment.
Special Business items include the appointment of M/s SPANJ & Associates as Secretarial Auditors for a term of five consecutive years (FY 2026-27 to FY 2030-31). The meeting will also seek approval for the appointment of Mr. Paresh Dhoti and Mrs. Disha Bharpoda as Independent Directors for a term of five years each, commencing from August 14, 2026, and August 24, 2026, respectively. Furthermore, the AGM will consider and approve revisions in the remuneration of Mr. Pragnesh Bharpoda, the Managing Director, from ₹18 lacs per annum to ₹36 lacs per annum, effective October 01, 2026, and Mrs. Bharti Pragnesh Bharpoda, the Whole-time Director and Chief Operating Officer, from ₹18 lacs per annum to ₹24 lacs per annum.
Other significant proposals include seeking approval under Section 180(1)(c) of the Companies Act, 2013, to enable the Board to borrow funds up to ₹500 Crores. Approval will also be sought under Section 180(1)(a) for the Board to sell, lease, or create charges on the company's assets to secure borrowings up to ₹500 Crores. Additionally, the members will vote on increasing the threshold for loans, guarantees, and investments under Section 186 of the Companies Act, 2013, up to ₹500 Crores, and to advance loans or provide guarantees/securities under Section 185 of the Companies Act, 2013.
Finally, the company will seek approval for related party transactions under Section 188 of the Companies Act, 2013. The Notice of the AGM, along with the Annual Report for FY 2025-26, is available on the company's website and the stock exchanges' websites. Shareholders will have the option to vote electronically through remote e-voting, which will be open from September 25, 2026, to September 27, 2026.
A plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.